- Home
- MGNX vs MG Comparison
MGNX vs MG Comparison
Compare MGNX & MG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- MG
- Stock Information
- Founded
- MGNX 2000
- MG 1978
- Country
- MGNX United States
- MG United States
- Employees
- MGNX N/A
- MG N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- MG Military/Government/Technical
- Sector
- MGNX Health Care
- MG Consumer Discretionary
- Exchange
- MGNX Nasdaq
- MG Nasdaq
- Market Cap
- MGNX 257.3M
- MG 288.7M
- IPO Year
- MGNX 2013
- MG 2009
- Fundamental
- Price
- MGNX $3.23
- MG $8.96
- Analyst Decision
- MGNX Hold
- MG Hold
- Analyst Count
- MGNX 10
- MG 1
- Target Price
- MGNX $7.17
- MG $11.00
- AVG Volume (30 Days)
- MGNX 465.7K
- MG 132.1K
- Earning Date
- MGNX 11-05-2024
- MG 10-30-2024
- Dividend Yield
- MGNX N/A
- MG N/A
- EPS Growth
- MGNX N/A
- MG N/A
- EPS
- MGNX N/A
- MG 0.36
- Revenue
- MGNX $141,329,000.00
- MG $738,983,000.00
- Revenue This Year
- MGNX $174.73
- MG $6.49
- Revenue Next Year
- MGNX N/A
- MG $2.75
- P/E Ratio
- MGNX N/A
- MG $25.57
- Revenue Growth
- MGNX 16.68
- MG 6.85
- 52 Week Low
- MGNX $2.95
- MG $7.09
- 52 Week High
- MGNX $21.88
- MG $12.44
- Technical
- Relative Strength Index (RSI)
- MGNX 42.79
- MG 45.38
- Support Level
- MGNX $3.10
- MG $8.59
- Resistance Level
- MGNX $3.30
- MG $9.13
- Average True Range (ATR)
- MGNX 0.19
- MG 0.32
- MACD
- MGNX 0.00
- MG 0.03
- Stochastic Oscillator
- MGNX 25.45
- MG 45.12
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.